Company ProfilePremium

AJOONI BIOTECH LTD

Company Profile Analysis

Ticker: AJOONI.NS

ESOMAR 23 Corporate BadgeISO Certifications Badge
AJOONI BIOTECH LTD - Company showcase

Year Founded & Workforce

2010

134 Employees

AJOONI BIOTECH LTD logo

AJOONI BIOTECH LTD Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

AJOONI BIOTECH LTD Overview

FieldDetailSource
Legal nameAjooni Biotech LimitedAnnual Report FY2025-26
Former nameAjooni Biotech Private Limited (17 Feb 2010 – 27 Sep 2017)Rights issue Letter of Offer 2024; ICICI Direct profile
Founding / incorporation date17 February 2010, at ChandigarhLetter of Offer 2024
Conversion to public company27 September 2017 (fresh certificate of incorporation, RoC Chandigarh)Letter of Offer 2024
Incorporation jurisdictionIndia; Registrar of Companies, Chandigarh (Punjab)Letter of Offer 2024
Corporate Identification NumberL85190PB2010PLC040162Annual Report FY2025-26
Registered officeD-118, Industrial Area, Phase VII, Mohali, Punjab 160055 (the AGM notice also uses PIN 160059)Annual Report FY2025-26
Corporate officeHouse No. 1769, Phase 3B2, Mohali, Punjab 160055Annual Report FY2025-26
Manufacturing worksGaib Di Pulli, Village Bullepur, Tehsil Khanna, District Ludhiana, Punjab 141401 (G.T. Road, Khanna)Annual Report FY2025-26
Stock exchange and ticker (current)National Stock Exchange of India, Main Board — symbol AJOONINSE filings 2026
Stock exchange and ticker (historical)NSE Emerge (SME), listed 2 Jan 2018 — migrated May 2022Letter of Offer 2024; press release Dec 2022
BSESeveral data vendors display BSE code 535040, but the company states its shares are listed only on NSE, and Upstox reports it as not listed on BSEDirectors' Report FY26 (Listing Fees section); Upstox
ISININE820Y01021 (current, after the October 2022 split); INE820Y01013 (pre-split)Directors' Report FY26; investor presentation June 2022
CUSIPNot applicable (no US listing)—
Fiscal year end31 MarchAnnual Report FY2025-26
Employees134 (latest, per Morningstar). A 3-year headcount trend is not publicly disclosed in the documents reviewed. Employee benefit expense rose from INR 1.80 Cr (FY24) to 2.76 Cr (FY25) and 4.57 Cr (FY26), which indicates a material workforce expansion linked to the new plant and the B2C dealer pushMorningstar; CMOTS; Annual Report FY26
Statutory auditorM/s Narinder Kumar and Company, Chartered Accountants, Mohali (FRN 0030737N; Peer Review Certificate 016014; engagement partner Narinder Kumar Garg, M.No. 080287). Appointed at the 14th AGM (17 Sep 2024) for five years to the 19th AGM (2029)Directors' Report FY26; Q1 FY27 Limited Review Report
Secretarial auditorM/s SDK & Associates, Punjab (PRC 7065/2025), FY2025-26 to FY2029-30Directors' Report FY26
Registrar and transfer agentCameo Corporate Services Ltd, ChennaiAnnual Report FY2025-26
BankerHDFC Bank Limited, G.T. Road, KhannaAnnual Report FY2025-26
Shares outstanding18,12,43,598 equity shares of INR 2 each, after the allotment of 90,00,000 shares on 12 Aug 2026; 17,22,43,598 as at 31 Mar 2026AGM Notice 2026; NSE allotment filing 12 Aug 2026
Market capitalisation (latest verified)About INR 65–70 Cr. Share price INR 3.79–3.90 between 28 Aug and 10 Sep 2026; Value Research showed INR 70 Cr on 1 Sep 2026. No quote for 19 Oct 2026 could be independently verifiedAnand Rathi; Value Research; Torus Digital
Websitehttps://ajoonibiotech.comAnnual Report FY2025-26

The supplied identifiers (ticker "AJOONI-SM.NS", exchange "National Stock Exchange of India") refer to the company's original listing on the NSE Emerge SME platform. That listing is outdated. Ajooni Biotech listed on NSE Emerge on 2 January 2018 and migrated to the NSE Main Board in May 2022 (source: rights issue press coverage, December 2022). The equity now trades under the symbol AJOONI on the NSE Main Board, and the NSE's Q2 FY26 integrated filing classifies the company as "Main Board". The entity profiled is unchanged: Ajooni Biotech Limited, CIN L85190PB2010PLC040162, website ajoonibiotech.com, India, NSE: AJOONI.

Ajooni Biotech is a Punjab-based micro-cap manufacturer of compound cattle feed, feed chips, camel feed, oil cakes and mineral and feed supplements. It positions itself as India's first listed "PURE VEG." animal-nutrition company, meaning formulations free of animal-derived inputs. The company runs a hybrid model. Historically most revenue has come from B2B and contract manufacturing for institutional buyers such as IFFCO Kisan, Mother Dairy, Paras (VRS Foods), Saahaj Dairy, NDDB Dairy Services and Patanjali-branded supplements. Since May 2024 it has also built its own "Ajooni" brand through a dealer network in north India. In FY26 a new Khanna plant tripled capacity to 1.8 lakh MTPA, and revenue rose 59% to INR 182.4 Cr. Margins, however, remain thin: EBITDA excluding other income was about 3.4% and PAT 2.4%. Returns on equity are about 5%. Large customer orders, promoter-group related-party ties and repeated equity dilution define the investment case.


The company's own description (Annual Report FY2025-26, paraphrased)

The FY26 Annual Report describes Ajooni as one of India's leading providers of animal nutrition and animal healthcare solutions. Its stated purpose is to raise dairy-farm productivity and livestock performance with scientifically formulated products. The portfolio spans compound cattle feed, cattle feed chips, camel feed, cotton oil cake, mustard oil cake and a range of feed supplements covering the livestock life cycle.

The company says it works with universities, research institutions and independent scientists on product development. It cites certifications under ISO 9001:2015, ISO 14001 (stated as "ISO:14000:2015"), ISO 45001 (stated as "ISO:45000:2018") and the ZED Gold scheme, together with BIS registration for ISI-marked feed and supplements. It also reports integrated ERP, PLC-based automated production controls, and environmental features at the plant (solar power, rainwater harvesting, a sewage treatment plant). Finally, it highlights a team of veterinary doctors and a field marketing force that provide doorstep technical service to customers.

For segment reporting, the Q1 FY27 results describe the business as a single segment ("Manufacturing of cattle feed and supplements") under Ind AS 108.

Independent characterisation

Ajooni is best understood as a regional, low-margin feed converter with an emerging brand layer:

  1. Contract and institutional manufacturing core (B2B). Ajooni makes feed to the specifications of large buyers, including cooperatives, agri-input marketers (IFFCO Kisan under an exclusive agreement from March 2020) and branded marketers (Patanjali Gramodhyog Nyas for Patanjali Samvriddhi, Garbhanjali and Batisa-Pro). These are high-volume, thin-margin relationships. Buyers have considerable pricing power because they can switch suppliers and dairy cooperatives cap feed prices to retain members (Mordor Intelligence notes this pressure on manufacturers' margins). The ₹47.52 Cr order from one existing customer in February 2026, about 26% of FY26 revenue (derived), shows how concentrated this channel is.

  2. Own-brand B2C channel. Launched in May 2024 in three states, including Punjab and Rajasthan. The company reported more than 100 dealers and a target of more than 300 distribution points (press release, 15 May 2024). Products include Gold Pashu Aahar, Buff Plus, 3 Star, 4 Star, Calf Starter and Transition Plus feeds, plus Calvit, Batisa, Liv and Min supplements (Morningstar company profile). The brand channel should carry better margins but needs working capital for dealer credit and inventory.

  3. Commodity trading and processing adjacencies. Cotton oil cake and mustard oil cake are by-products traded as feed ingredients. Their prices follow oilseed cycles.

  4. Optionality projects of uncertain status. In May 2024 the company announced moringa cultivation at Derabassi, Punjab, aimed at nutraceutical, feed and biodiesel uses, with management projecting an additional ₹150–200 Cr of annual revenue. No subsequent filing reviewed quantifies progress, so this should be treated as unproven.

Revenue model mix. Ajooni earns essentially all its revenue from product sales. It has no service, subscription or licensing income. The split between contract/B2B and own-brand sales is not publicly disclosed. Other income was ₹2.42 Cr in FY26, or 1.3% of revenue (Directors' Report FY26). This is a material share of a profit base of only ₹5.74 Cr PBT.

Value-chain position. The company sits mid-stream. It buys grains, de-oiled cakes, brans, molasses, minerals and vitamins. It processes them by grinding, mixing and pelleting or chipping, then sells feed to cooperatives, agri-marketers, dealers and, to a small extent, export customers (Avon Animal Health orders; exports "to two countries" per a 2024 DSIJ report). It neither owns herds nor controls milk procurement, so it captures none of the downstream dairy margin.

Customer types: (i) dairy cooperatives and milk processors, including Mother Dairy, Paras Dairy/VRS Foods, Saahaj Dairy and an unnamed "leading dairy cooperative" that placed a ₹25 Cr repeat order in August 2025; (ii) agri-input marketers (IFFCO Kisan); (iii) branded marketers (Patanjali Gramodhyog Nyas); (iv) government and quasi-government dairy bodies (NDDB Dairy Services contract, 2024; Directorate of Dairy Development, Punjab, cited in presentations); (v) dealers and farmers under the Ajooni brand; and (vi) small export customers.

End-markets: dairy cattle and buffalo nutrition, which is the core, plus camel feed (a niche relevant to Rajasthan) and adjacent feed-ingredient trading.

Strategy

Stated strategy themes (Annual Report FY26, MD's message, paraphrased)

  1. Capitalise on India's dairy growth. India is the world's largest milk producer and has the largest livestock population, and management says demand for quality feed is structural.

  2. A "new phase of growth and transformation". Management describes a strategic roadmap covering manufacturing, sales and marketing, procurement and supply chain, built around the newly commissioned integrated plant.

  3. Operational efficiency and resilience. The company acknowledges raw-material price volatility, supply-chain pressure and a "challenging industry landscape" in Q4 FY26, and commits to cost control and efficiency.

  4. Quality and certification as a differentiator. BIS ISI marking, ISO and ZED Gold certifications, and the "PURE VEG." positioning.

  5. Sustainability. Solar power, rainwater harvesting and a sewage treatment plant at the manufacturing facility.

Initiative register (last 24 months, Oct 2024 – Oct 2026)

InitiativeDate announcedDescriptionTarget / KPIStatusSource
New 1,20,000 MTPA plant, KhannaOngoing; target Nov 2025 (Aug 2025 update)Capacity expansion to 1,80,000 MTPA with modern automationLower unit cost, margin expansionCommercial production by Feb 2026; Q1 FY27 margins compressedDSIJ Aug 2025; Indian Pharma Post Feb 2026
Convertible warrants (₹45 Cr)6 Jan 20255 Cr warrants at ₹9 to promoters and investorsStrengthen capital baseEGM approved on 3 Feb 2025; no allotment reflected in share capital to 31 Mar 2026; status unconfirmedPress release 6 Jan 2025; Directors' Report FY26
Authorised capital to ₹50 Cr6 Jan 2025Capital headroom—CompletedPress release 6 Jan 2025
Merger of Healthy Biosciences Ltd into AjooniFeb 2026 (board discussion)Amalgamation of the promoter entity"Strategic expansion"Exploratory; no scheme or valuation filed in the material reviewedIndian Pharma Post; Aliceblue
Preferential issue to promoter (₹3.87 Cr)29 Jun 202690 lakh shares at ₹4.30Fund warehousing (₹3.67 Cr) and general purposes (₹0.20 Cr)Allotted on 12 Aug 2026AGM Notice 2026; NSE filing
Raw-material warehousing29 Jun 2026About 50,000 sq ft, about 10,000 MT storage at BullepurProcurement efficiency; buy commodities in seasonWithin one year of Aug 2026AGM Notice 2026
Authorised capital to ₹70 Cr29 Jun 2026Adds 10 Cr shares of headroom"Increased fund requirements and future plans"Approved at 29 Jul 2026 AGMAGM Notice 2026
Own-brand B2C expansionMay 2024 (continuing)Dealer network expansion beyond 100 dealersMore than 300 distribution pointsProgress not updated publiclyPress release 15 May 2024
Moringa diversificationMay 2024Cultivation for nutraceutical, feed and energy uses₹150–200 Cr incremental annual revenueNo disclosed progressPress release 21 May 2024
BIS-certified mineral mixtureNov 2024Certified supplement lineQuality-led supplement growthCompletedPress release 18 Nov 2024

Medium-term targets and guidance

  • The May 2024 B2C press release included "AJOONI's Projection for Next 3 Years" running to FY2026-27.

  • No formal revenue or margin guidance appears in the FY26 Annual Report. The MD's message is qualitative.

Cost programme with quantified targets: none disclosed.

Products & Services

All products sit in the single segment. Pricing is not publicly disclosed for any product. The catalogue below is assembled from the Annual Report FY26, investor presentations (2022, 2024), the Morningstar company profile and press releases.

Compound cattle feed (own brand "Ajooni")

ProductDescription and functionTarget customerLaunch / statusSource
Gold Pashu AaharPremium compound cattle feed for milch animalsDairy farmers via dealersMarketed under own brand (B2C push from 2024)Morningstar profile
Buff PlusCompound feed formulated for buffaloes, which dominate Punjab and Haryana milk productionBuffalo dairy farmersCurrentMorningstar profile
3 StarMid-tier compound cattle feedPrice-sensitive smallholdersCurrentMorningstar profile
4 StarHigher-protein, higher-energy compound cattle feedHigher-yield herdsCurrentMorningstar profile
Calf StarterStarter ration for calves to support rumen developmentCalf rearers, dairy farmsCurrentMorningstar profile
Dairy Calf GrowerGrower ration for heifersDairy farmsListed in the 2022 own-product portfolioInvestor presentation June 2022
Transition PlusTransition-cow feed for the periparturient periodCommercial dairiesCurrentMorningstar profile

Feed formats and other feeds

ProductDescriptionTarget customerSource
Compound Cattle Feed (pellet/mash)Core volume product, ISI-marked under BISCooperatives, agri-marketers, dealersAnnual Report FY26
Cattle Feed ChipsChipped feed formatInstitutional buyersAnnual Report FY26
Camel FeedNiche formulation for camelsRajasthan and arid-region buyersAnnual Report FY26
Cotton Oil CakeProtein-rich feed ingredient (by-product of cottonseed crushing)Feed manufacturers, farmersAnnual Report FY26
Mustard Oil CakeProtein-rich feed ingredient (by-product of mustard crushing)Feed manufacturers, farmersAnnual Report FY26

Feed supplements (own brand)

ProductDescription (inferred from naming and company materials)Source
CalvitCalcium and vitamin supplementMorningstar profile
BatisaHerbal/digestive supplementMorningstar profile
LivLiver-support supplementMorningstar profile
MinMineral mixture. The mineral mixture received BIS certification in November 2024Morningstar profile; press release 18 Nov 2024

Contract-manufactured and co-branded products

ProductBrand owner / channelDescriptionSource
Patanjali SamvriddhiPatanjali Gramodhyog NyasCattle feed supplementVentura; Zerodha profile; investor presentation May 2024
Patanjali GarbhanjaliPatanjali Gramodhyog NyasSupplement for pregnant animalsSame
Patanjali Batisa-ProPatanjali Gramodhyog NyasDigestive/herbal supplementSame
IFFCO-branded animal feedIFFCO Kisan (exclusive agreement, March 2020)ISI-marked "PURE VEG." cattle feedInvestor presentations 2022 and 2024
Institutional cattle feedMother Dairy, Paras Dairy (VRS Foods), Saahaj Dairy, NDDB Dairy Services, unnamed cooperativesFeed to buyer specificationInvestor presentations; press releases 2024–2026
Export feed supplementsAvon Animal Health (export and repeat orders)Feed supplementsReuters headlines via Zerodha (dates not specified)

Development-stage initiatives

InitiativeDescriptionStatusSource
Moringa cultivationNursery and plantation at Derabassi, Punjab, for leaves (nutraceutical and feed ingredient), seed oil (biodiesel and aviation-fuel feedstock) and bark (activated carbon). Management projected ₹150–200 Cr additional annual revenueNo progress or revenue disclosed after 2024Press release 21 May 2024; DSIJ

Financial Narrative

Basis. FY2025 and FY2026 come from the Directors' Report FY26 and the audited results of 28 May 2026. FY2022–FY2024 P&L items come from CMOTS data (Arihant Capital), which matches company-reported FY25 PBT of ₹4.33 Cr. Balance-sheet items for FY22–FY25 come from IIFL and Bajaj Broking, and FY26 from the audited Statement of Assets & Liabilities. Cash-flow history comes from StockAnalysis and should be treated as vendor-derived. All figures are in INR Cr unless noted.

Per-share data

FY26 EPS of ₹0.25 is as reported (FY26 results). Earlier EPS figures are analyst-derived on year-end share counts and are not adjusted for the bonus element of the rights issues. The company's reported historical EPS may therefore differ. The Q1 FY27 results template labels EPS "Face Value of Rs.10/- each", which is a labelling error because face value has been ₹2 since October 2022.

Margins

Revenue CAGR. FY2022–FY2026 (4 years): 25.3%. FY2021–FY2026 (5 years, FY21 revenue ₹51.04 Cr per CMOTS): about 29.0%. Value Research reports a 5-year revenue growth score of 30.1%, consistent with this.

Commentary. Revenue followed a step-function pattern: a pandemic-era jump in FY22, flat sales in FY23–FY24, then rapid growth in FY25–FY26. The FY26 increase came from large institutional orders (₹25 Cr in August 2025, ₹4.8 Cr in September 2025, ₹47.52 Cr in February 2026) and new capacity reaching production in the second half. Quarterly revenue almost doubled from about ₹31 Cr in Q1/Q2 FY26 to ₹58.75 Cr in Q3 and ₹60.62 Cr in Q4.

Gross margin widened to 18.9%, but most of that gain was absorbed by "other expenses" (₹23.62 Cr, up from about ₹10 Cr) and by employee costs. As a result, EBITDA margin excluding other income improved only modestly to 3.4%. Other income has been between ₹2.07 Cr and ₹2.42 Cr in each of the last three years, equal to 42–73% of PBT. Core operating profitability is therefore materially weaker than headline PAT suggests. For example, FY24 PBT of ₹3.00 Cr included ₹2.19 Cr of other income.

Quarterly trajectory (INR lakh)

Sources: Q1 FY27 results (Q1FY26, Q4FY26, Q1FY27); Q2 FY26 integrated filing; Capital Market/Arihant for Q3 FY26 (sales ₹58.75 Cr, PBT ₹2.36 Cr, PAT ₹1.65 Cr, rounded).

Inflection in Q1 FY27. Revenue was ₹63.49 Cr (+103% YoY), but PAT fell 45% YoY to ₹43.18 lakh. Derived gross margin compressed to 14.7%, against 18.9% in Q4 FY26 and 18.1% in Q1 FY26. Finance costs rose almost six-fold YoY to ₹48.21 lakh, and depreciation more than tripled to ₹80.27 lakh because of the new plant. Derived EBITDA margin excluding other income was about 2.6%. The pattern is consistent with large low-margin institutional volumes being run through a higher fixed-cost base financed by short-term debt.

Balance sheet

Debt maturity split (INR Cr)

Sources: Directors' Report FY26 item 34 (₹1,776.29 lakh versus ₹193.96 lakh); audited and Q1 FY27 Statements of Assets & Liabilities.

Balance-sheet observations

Loans and other financial assets are large: At 31 March 2026 the company held ₹15.00 Cr of non-current "other financial assets" and ₹14.15 Cr of current "loans", about ₹29 Cr or 24% of total assets (audited Statement of Assets & Liabilities). The counterparties and terms were not identifiable in the material reviewed. During the same period the company drew ₹16.22 Cr of short-term borrowings. Lending or advancing funds while borrowing to finance working capital needs to be explained, especially given the promoter-group related parties.

Inventory build: Inventory rose to ₹39.46 Cr at FY26 and ₹41.81 Cr at 30 June 2026. That equals about 97 days of material consumption (derived), up from about 34 days in FY22.

Non-current investments: of ₹2.45 Cr produced an other-comprehensive-income loss of ₹1.21 Cr in FY26. Total comprehensive income was therefore ₹3.11 Cr, against PAT of ₹4.32 Cr.

Cash flow

Cash-flow figures come from StockAnalysis, converted from INR million. Sources conflict. Bajaj Broking shows different operating cash-flow values for the same years, for example −₹3.40 Cr and −₹5.13 Cr against StockAnalysis's ₹22.91 Cr and −₹5.58 Cr in the corresponding columns. The original filed cash-flow statements should be used for any investment decision. Equity raised is derived from share-capital changes multiplied by issue prices. The FY25 column reflects the June 2024 rights issue (FY2024-25).

Commentary. Cumulative FY22–FY26 free cash flow is about −₹31.6 Cr on these vendor figures. Cumulative PAT over the same period is ₹12.0 Cr, and roughly ₹65 Cr of equity was raised over the period. Growth has been funded almost entirely by shareholders and, since FY26, by short-term bank debt. Earnings have not converted into cash.

Ratios

All ratios are analyst-derived. Cash conversion cycle for FY26: about 111 days (97 days inventory + 36 days receivables − 22 days payables, with trade payables of ₹8.91 Cr). Payables are not available for earlier years, so the cycle is not computed for them.

Interpretation. Returns have stayed in a narrow 4–7% band for five years, well below India's cost of equity. Capital has been raised and deployed at returns that destroy value. Leverage rose in FY26 for the first time in three years, and on Q1 FY27 annualised EBITDA (about ₹7.8 Cr including other income) net debt of ₹26.5 Cr is roughly 3.4x (derived). Receivable days have improved sharply, which is consistent with cooperatives and institutional buyers paying faster. That improvement has been more than offset by inventory build-up.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment and Segment Margins & Growth (%)

MetricFY2024FY2025FY2026

Segment revenue — cattle feed and supplements (INR Cr)

80.11114.69182.38

Segment PBT (INR Cr)

3.004.335.74

Segment PBT margin (%)

3.743.783.15

YoY revenue growth (%)

7.543.259.0

Contribution to total revenue (%)

100100100

Income Statement and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Revenue from operations (INR Cr)

74.0474.4980.11114.69182.38

Revenue growth YoY (%)

45.10.67.543.259.0

Other income (INR Cr)

0.040.292.192.072.42

Gross profit — revenue minus materials (INR Cr, derived)

10.038.759.7617.6734.46

EBITDA excluding other income (INR Cr, derived)

3.072.772.243.696.26

EBITDA including other income (INR Cr)

3.113.064.435.768.67

Depreciation and amortisation (INR Cr)

1.111.000.871.092.21

Operating income / EBIT incl. other income (INR Cr)

2.002.063.564.666.47

Finance costs (INR Cr)

0.540.480.560.330.73

Pre-tax income (INR Cr)

1.461.583.004.335.74

Tax (INR Cr)

0.410.450.840.961.42

Net income (INR Cr)

1.051.132.163.374.32

Employee benefit expense (INR Cr)

1.481.761.802.764.57

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

EPS basic (INR, FV 2; FY22–FY25 derived on year-end shares)

0.210.130.250.200.25

EPS diluted (INR)

0.210.130.250.200.25

Dividend per share (INR)

00000

Year-end shares outstanding (Cr)

5.008.768.7617.2217.22

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Gross margin (%)

13.511.712.215.418.9

EBITDA margin excl. other income (%)

4.153.722.803.223.43

Operating (EBIT) margin (%)

2.702.774.444.063.55

Pre-tax margin (%)

1.972.123.743.783.15

Net margin (%)

1.421.522.702.942.37

Income Statement

MetricQ1FY26Q2FY26Q3FY26Q4FY26Q1FY27

Revenue from operations (INR Lakh)

3,126.773,173.515,8756,062.216,349.07

Profit before tax (INR Lakh)

102.72123.37236112.0365.44

Net profit (INR Lakh)

78.1493.2116594.7243.18

Finance costs (INR Lakh)

8.460028.9548.21

Depreciation (INR Lakh)

24.830089.7980.27

Balance Sheet

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (INR Cr)

29.0258.7347.5295.05120.37

Cash and equivalents (INR Cr)

0.060.310.436.830.42

Total debt (INR Cr)

5.355.182.171.9417.76

Net debt (INR Cr)

5.294.871.74-4.8917.34

Shareholders' equity (INR Cr)

16.3941.6742.7188.0891.19

Goodwill and intangibles (INR Cr)

0000.480.36

Inventories (INR Cr)

5.886.9915.3723.9939.46

Trade receivables (INR Cr)

13.8420.5512.9616.2217.83

Net working capital (INR Cr)

11.8719.4629.3257.1847.13

Financial Analysis

Item31 Mar 202531 Mar 202630 Jun 2026

Long-term borrowings

1.941.541.41

Short-term borrowings

0.0016.2225.50

Total borrowings

1.9417.7626.91

Cash and equivalents

6.830.420.37

Net debt

-4.8917.3426.54

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (INR Cr)

3.68-5.5822.91-17.74-5.73

Capital expenditure (INR Cr)

2.121.365.602.0318.03

Free cash flow (INR Cr)

1.56-6.9417.31-19.77-23.76

Dividends paid (INR Cr)

00000

Share buybacks (INR Cr)

00000

Equity raised (INR Cr, derived)

022.5042.30

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2022FY2023FY2024FY2025FY2026

ROE on average equity (%)

6.63.95.15.24.8

ROA on average assets (%)

3.72.64.14.74.0

ROIC, post-tax EBIT / (equity + debt − cash) (%)

6.63.15.84.34.5

Current ratio (x)

2.182.2810.7412.862.72

Debt-to-equity (x)

0.330.120.050.020.19

Net debt / EBITDA incl. other income (x)

1.701.590.39-0.852.00

Interest coverage, EBIT / finance cost (x)

3.74.36.413.98.9

Asset turnover (x)

2.601.701.511.611.69

Inventory days on material cost

33.638.680.390.197.3

Receivable days on revenue

68.2100.759.051.635.7

Revenue by Region and Region Margins & Growth (%)

RegionFY2024FY2025FY2026

India — all channels (INR Cr)

80.11114.69182.38

India growth YoY (%)

7.543.259.0

Region Overview

RegionEvidenceAssessment

Punjab (home market)

Plant at Khanna; Directorate of Dairy Development, Punjab, cited as an institutional link; own-brand launch state

Core volume base; freight advantage within roughly 300 km

Rajasthan

Own-brand launch state; camel-feed niche

Growth market for brand and niche feeds

Third own-brand state

Not named in the material retrieved (press release 15 May 2024 lists three states)

—

National institutional buyers

IFFCO Kisan, Mother Dairy (Delhi NCR), Paras/VRS Foods (UP/NCR), Saahaj (UP), NDDB Dairy Services

Pan-north-India institutional demand

Exports

Avon Animal Health orders

De minimis

“—” = not publicly disclosed.

Share Price & Returns

WindowReturn (%)Reference pointSource

3 months (to 6 Aug 2026)

-8.76—

Ventura

6 months (to 28 Aug 2026)

-17.79—

Anand Rathi

1 year (to 28 Aug 2026)

-29.68—

Anand Rathi

3 years (to 28 Aug 2026)

6.16

Value Research shows 3.4% to 21 Jul 2026

Anand Rathi; Value Research

5 years (to 6 Aug 2026)

-54.88 (CAGR -14.72)

—

Ventura

52-week range

₹3.40 (8 Jun 2026) to ₹5.94

—

Ventura; Value Research

All-time high

₹12.72 (9 Feb 2022)

—

Ventura

Latest verified price

₹3.90 (10 Sep 2026); ₹3.79 (28 Aug 2026)

—

Torus; Anand Rathi

Monthly close Mar 2025

₹5.60 (market cap ₹96.46 Cr)

—

Arihant Capital

Valuation Multiples

MultipleAjooniPeer referenceSource / basis

Market cap

About ₹70 Cr

—

18.12 Cr shares × about ₹3.85

P/E (TTM, Q2 FY26 – Q1 FY27 PAT ₹3.96 Cr)

About 17.6x

Peer median 30.68x (Value Research, Jul 2026); Godrej Agrovet 34.7x

Derived; Value Research; Tickertape

P/B (book about ₹95.5 Cr post-allotment)

About 0.73x

Peer median 1.68x (Value Research); KSE 3.07x; Godrej Agrovet 3.81x

Derived

EV (market cap + ₹26.91 Cr debt − ₹0.37 Cr cash)

About ₹96.5 Cr

—

Derived

EV/EBITDA (FY26 EBITDA incl. other income ₹8.67 Cr)

About 11.1x

—

Derived

EV/Sales (TTM revenue ₹214.6 Cr)

About 0.45x

—

Derived

Dividend yield

0%—

No dividends ever paid

Bucket Details

BucketINR Cr

Short-term borrowings (≤ 12 months, working capital)

25.50

Long-term borrowings (> 12 months)

1.41

Total

26.91

Capital Markets

ItemValue

Authorised capital

₹70 Cr (35 Cr shares of ₹2), approved 29 Jul 2026

Paid-up capital

₹36.25 Cr (18,12,43,598 shares), derived after the Aug 2026 allotment

Outstanding warrants

Status of the Jan 2025 programme is unconfirmed; no conversions reflected in paid-up capital

Analyst Conclusions

Management guidance

No quantitative guidance is in force. Management's FY26 commentary describes a "new phase of growth and transformation" built on the new plant and a roadmap across manufacturing, sales, procurement and supply chain (MD's message, Annual Report FY26).

Consensus expectations

None available.

Run-rate reference (derived). Q1 FY27 revenue annualises to about ₹254 Cr and Q1 FY27 PAT to about ₹1.7 Cr. That profit run-rate is well below FY26 PAT of ₹4.32 Cr, unless margins recover or other income normalises upward.

Bull case

  1. Operating leverage on new capacity. Revenue doubled YoY in Q1 FY27. If gross margin returns to the FY26 level of about 19% from 14.7%, while depreciation and employee costs are now largely fixed, EBITDA could expand disproportionately. In Q3 FY26 the company achieved a 5.16% OPM.

  2. Deep value on book. At about 0.73x P/B and about 0.45x EV/Sales, the market already prices in sub-par returns. Small improvements in ROE from about 5% could drive re-rating, especially with promoter buying at ₹4.30 in August 2026.

  3. Institutional demand validation. Repeat large orders (₹25 Cr, ₹47.52 Cr) from top cooperatives and NDDB Dairy Services, plus IFFCO exclusivity, provide volume visibility in a market growing at about 6.4% annually.

Bear case

  1. Value-destructive growth. Five years of ROE between 3.9% and 6.6%, cumulative negative FCF of about ₹32 Cr, and about ₹65 Cr of equity raised since FY22 against ₹12 Cr of cumulative PAT show that growth has not created shareholder value. Q1 FY27 PAT fell 45% YoY despite revenue doubling.

  2. Balance-sheet quality and leverage. About ₹29 Cr sits in loans and other financial assets of undisclosed nature while short-term debt has risen to ₹25.50 Cr. Cash is ₹0.37 Cr, and finance costs are rising steeply.

  3. Governance and dilution overhang. The promoter holds 30.5%. Combined Chairman/MD/CFO roles, independent directors shared with the promoter entity, a pending related-party merger, and authorised capital raised to 35 Cr shares all point to further dilution and minority-shareholder risk.

Catalysts and monitorables (next 12 months)

Catalyst / monitorableExpected timingWhat to watch
Q2 FY27 resultsBy mid-November 2026Gross margin recovery above 17%; finance cost trend; inventory and debt levels
Q3 FY27 resultsLate January / February 2027Execution and margin of the ₹47.52 Cr-type orders
Healthy Biosciences mergerAny timeScheme filing, swap ratio, independent valuation, NSE and NCLT process
Disclosure on loans and advancesFY27 annual report / AGMCounterparties and related-party nature of ₹29 Cr in financial assets
Further equity issuanceAny time (headroom created)Pricing, allottees, related-party involvement
Warehouse capex completionBy about August 2027Procurement savings
New large ordersOngoingCustomer diversification versus concentration
Status of January 2025 warrantsAny timeFormal lapse or conversion disclosure
Commodity prices (maize, cottonseed and mustard cake)ContinuousGross-margin sensitivity

Analyst verdict

Ajooni Biotech has turned itself, in volume terms, from a ₹74 Cr regional feed miller into a ₹180–250 Cr run-rate business with three times its former capacity. On revenue, the past two years mark a genuine inflection. The new Khanna plant, credentials with IFFCO Kisan, Mother Dairy, NDDB Dairy Services and Patanjali, and repeated cooperative orders show that the company can win and execute large institutional volumes in a structurally growing market.

Value creation, however, is about returns on capital, and the record there is poor. Return on equity has stayed between 4% and 7% for five years. Free cash flow has been persistently negative. Each phase of growth has been paid for with new equity: the share count has risen 3.6x since FY22, and authorised capital has just been raised again. Headline profit depends on other income, and the core business earns an EBITDA margin of about 3%. The first quarter on the new asset base (Q1 FY27) showed the risk plainly: revenue doubled while net profit nearly halved, because commodity costs, depreciation and interest all hit together.

Governance needs the most scrutiny. The founder is Chairman, MD and CFO. Two independent directors also sit on the board of the promoter entity, which has just been allotted shares and is a candidate for amalgamation. About ₹29 Cr of loans and financial assets sit on the balance sheet without clear disclosure while the company borrows short-term.

The stock's discount to book (about 0.7x) is therefore justified rather than an anomaly. An investment case requires evidence on three fronts: (1) gross margins returning to about 19% at scale, so that EBITDA margins move toward 5%; (2) transparent disclosure of the loan book and arm's-length terms for any Healthy Biosciences merger; and (3) a pause in dilution. Until then, Ajooni is a high-risk, governance-sensitive micro-cap suited to monitoring rather than accumulation. The Q2 and Q3 FY27 results are the key tests.


Appendix A — Data reconciliation notes

  1. Revenue definitions. StockAnalysis reports FY26 revenue of ₹184.8 Cr including other operating revenue, and Value Research reports ₹182 Cr TTM.

  2. FY25 revenue. Torus reports ₹116.76 Cr (likely total income) against company revenue from operations of ₹114.69 Cr. The company figure is used.

  3. Cash-flow history. StockAnalysis and Bajaj Broking conflict materially. Neither has been verified against the filed cash-flow statements.

  4. Ventura's Q4 FY26 revenue figure of "₹587.53 Cr" is a vendor data error. The actual figure is ₹60.62 Cr (₹6,062.21 lakh).

  5. FY25 PBIT is printed as ₹4,33,35,012 in the FY26 Directors' Report. Arithmetic (PBDIT ₹575.70 lakh minus depreciation ₹109.35 lakh) gives ₹466.35 lakh, so the printed figure appears to be a typographical error.

  6. Accounting framework. The Directors' Report cites "Accounting Standards 21" in one place and Ind AS elsewhere. The results are stated to be prepared under Ind AS.

  7. Screener's description of Ajooni as active in "aquaculture" is not supported by any company filing reviewed.

  8. BSE listing. Vendors show BSE code 535040, but the company states NSE as its only listing.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameDesignationDINTenure / appointmentBackgroundAgeFY26 remuneration (INR Lakh)

Jasjot Singh

Chairman, Managing Director and CFO (promoter)

01,937,631

Director since 4 Sep 2017 (per MarketScreener); re-designated MD w.e.f. 1 Apr 2025

Founder.

—

52.00 (salary and perquisites)

Gursimran Singh

Whole-Time Director (CEO for about 8 years)

02,209,675

Board since 13 Aug 2020; WTD w.e.f. 14 Aug 2025; reappointed on rotation at the 2026 AGM

B.Com, MBA; more than 15 years in animal husbandry and crop/supplement cultivation; director of Healthy Biosciences Ltd; holds 1,915 Ajooni shares

38 (born 23 Feb 1988)

12.65

Partek Singh

Executive Director

07,864,006

Not publicly disclosed (DIN series suggests about 2017)

——

Nil

Simmi Chhabra

Independent Director (woman); chairs Audit, NRC and SRC

07,870,398—

Not publicly disclosed; holds 100 shares

—

0.49 (sitting fees)

Ramandeep Singh

Independent Director

07,896,086—

Also an Independent Director of Healthy Biosciences Ltd (the promoter entity); holds 20,400 shares

—0.49

Imteshwar Singh (Bhatia)

Independent Director

07,864,007———0.49

Ishtneet Bhatia

Independent Director

10,440,990

Not publicly disclosed (DIN issued about 2024)

Also an Independent Director of Healthy Biosciences Ltd

—0.29

Total

—————

66.41

“—” = not publicly disclosed.

Executive Leadership Team

NameRoleNotes

Jasjot Singh

MD and CFO

The CFO role is combined with the MD role

Swati Vijan

Company Secretary and Compliance Officer (FCS 13627)

Remuneration not publicly disclosed in the material reviewed

Board & Management Changes

DateChangeContext

1 Apr 2025

Jasjot Singh re-designated Managing Director

Formalises founder's executive role

14 Aug 2025

Gursimran Singh re-designated Whole-Time Director

Elevates long-serving CEO to the Board in an executive capacity

29 Jul 2026

Gursimran Singh reappointed on retirement by rotation

Routine

FY26

No director resignations

Corporate Governance Report FY26

Shareholding Pattern

CategoryShares (pre-allotment, Jun 2026)%Shares (post-allotment, Aug 2026)%

Promoter — individuals

4,63,24,766

26.89

4,63,24,766

25.56

Promoter — Healthy Biosciences Ltd

00.00

90,00,000

4.97

Total promoter group

4,63,24,766

26.89

5,53,24,766

30.53

Public — resident individuals

11,28,52,316

65.52

11,28,52,316

62.27

Public — NRIs

54,48,663

3.16

54,48,663

3.01

Public — bodies corporate

37,72,705

2.19

37,72,705

2.08

Public — HUF, LLP and others

38,45,148

2.23

38,45,148

2.12

Institutions (FII, DII, MF, banks)

00.0000.00

Total

17,22,43,598

100

18,12,43,598

100

Competitive Landscape

Key Competitors

CompetitorTypeOverlap with AjooniScale indicatorRelative positioning

Godrej Agrovet Ltd

Listed diversified agri-business

Cattle, poultry and aqua feed nationally; north-India cattle feed

Consolidated FY26 revenue above ₹10,000 Cr; Animal Feed segment ₹3,672 Cr in 9M FY26; cattle feed volumes +18–24% in FY26

National leader in branded compound feed, with scale and R&D far beyond Ajooni

KSE Ltd

Listed cattle feed and dairy (Kerala)

Pure-play compound cattle feed

FY26 revenue ₹1,680 Cr; PAT ₹84.04 Cr; Q1 FY27 PAT ₹0.94 Cr

Closest listed pure-play peer; dominant in Kerala, not in north India

Amul / GCMMF and member unions

Cooperative

Cattle feed plants serving member farmers

Not disclosed separately

Price-setter in Gujarat; cooperatives cap feed prices

Punjab State Cooperative Milk Producers' Federation (Milkfed, "Verka")

State cooperative

Cattle feed in Punjab, Ajooni's home market

—

Direct regional competitor with captive milk-procurement access

Cargill India (Purina)

Multinational (unlisted in India)

Compound and specialty feeds

—

Premium technology-led player

Anmol Feeds

Private

Poultry, cattle and fish feed (east and north India)

—

Larger regional private feed miller

Kapila Krishi Udyog (Kapila Pashu Aahar)

Private

Cattle feed (Maharashtra and national)

—

Established cattle feed brand

SKM Animal Feeds & Foods

Private

Cattle and poultry feed (south India)

—

Regional private

Mayank Cattle Food Ltd

Listed (SME)

Cattle feed (Gujarat)

—

Small listed peer of similar scale

Avanti Feeds Ltd

Listed

Aqua feed (adjacent category; Ajooni has no aqua product despite Screener's "aquaculture" label)

—

Adjacent, not a direct competitor

Venky's (India) Ltd

Listed

Poultry feed (adjacent)

—

Adjacent

Unorganised local feed mixers and farm-mixed rations

Informal

Price-led competition for smallholders

Not measurable

The largest de facto competitor in rural Punjab

“—” = not publicly disclosed.

Peer Comparison FY2026

MetricAjooni Biotech (FY26)KSE Ltd (FY26)Godrej Agrovet (FY26)Godrej Agrovet — Animal Feed segment

Revenue (INR Cr)

182.41,680—

3,672 (9M FY26)

Revenue growth YoY (%)

59.01.9—

1.0 (9M FY26 YoY)

Net profit (INR Cr)

4.3284.04——

Net margin (%)

2.4

5.0 (derived)

——

P/E (x)

About 17–18 (TTM, Sep 2026, derived)

Negative/not meaningful on TTM (Tickertape)

34.7 (Tickertape)

—

P/B (x)

About 0.7

3.07 (Tickertape)

3.81 (Tickertape)

—

Company Snapshot

$21.1M

Revenue

134

Employees

2010

Founded

SWOT Analysis

Strengths

  • Rapid top-line growth. Revenue rose 59% to ₹182.38 Cr in FY26 after 43% in FY25 (Directors' Report FY26), and Q1 FY27 revenue was ₹63.49 Cr (+103% YoY).
  • Expanded, modern capacity. The new 1,20,000 MTPA plant takes total capacity to 1,80,000 MTPA. Capital work-in-progress was nil at June 2026, so the plant is fully operational and capitalised (Q1 FY27 Statement of Assets & Liabilities).
  • Blue-chip institutional customers. IFFCO Kisan (exclusive since March 2020), Mother Dairy, Paras/VRS, Saahaj, NDDB Dairy Services and Patanjali Gramodhyog Nyas (investor presentations 2022 and 2024; press release May 2024).
  • Quality certifications. BIS ISI marking, ISO 9001/14001/45001 and ZED Gold, plus BIS-certified mineral mixture (Annual Report FY26; press release Nov 2024).
  • Order momentum. ₹25 Cr (Aug 2025), ₹4.8 Cr (Sep 2025) and ₹47.52 Cr (Feb 2026) orders; the last was the largest in company history.
  • Improved receivable collection. Receivable days fell from 100.7 (FY23) to 35.7 (FY26) (derived from IIFL and audited data).
  • Clean audit opinion. No qualification, reservation or adverse remark, and no fraud reported under Section 143(12) (Directors' Report FY26).

Weaknesses

  • Thin core margins. EBITDA excluding other income was 3.43% in FY26 and about 2.6% in Q1 FY27 (derived).
  • Dependence on other income. ₹2.42 Cr of other income equalled 42% of FY26 PBT, and ₹2.19 Cr equalled 73% of FY24 PBT.
  • Sub-par returns. ROE between 3.9% and 6.6% throughout FY22–FY26 (derived).
  • Persistent negative free cash flow. FCF was −₹19.8 Cr in FY25 and −₹23.8 Cr in FY26 on StockAnalysis figures.
  • Governance concentration. Chairman, MD and CFO roles are combined in one person, and two independent directors also sit on the promoter entity's board (Corporate Governance Report FY26).
  • Low promoter skin in the game. Promoter holding was 26.89% before the August 2026 allotment and 30.53% after it (AGM Notice 2026).
  • Compliance lapses. Late newspaper publication of results (Reg. 47) and a late Reg. 74(5) filing (Secretarial Audit FY26). The filings also contain numerous clerical errors, for example the EPS face-value label, a board meeting date of "30.01.2025" cited in the FY26 report, and a Q1 FY27 board approval date shown as 12.08 rather than 14.08.

Opportunities

  • Capacity utilisation upside. A plant sized at 1,80,000 MTPA against an FY26 base of ₹182 Cr leaves room for operating leverage if margins stabilise.
  • Own-brand B2C expansion. Target of more than 300 distribution points (press release 15 May 2024) could lift mix and margins.
  • Industry tailwind. India compound feed growing at about 6.4% CAGR to USD 21 bn by 2031; supplements at 8.05% CAGR (Mordor).
  • Procurement efficiency. About 10,000 MT of raw-material storage (₹3.67 Cr capex) would allow seasonal buying of oil cakes and grains (AGM Notice 2026).
  • Export development. Avon Animal Health orders show export potential.
  • Moringa optionality. Management has projected ₹150–200 Cr of potential revenue (May 2024), though this is unproven.

Threats

  • Commodity volatility. Q1 FY27 gross margin fell to 14.7% from 18.9% in Q4 FY26 (derived from the Q1 FY27 results).
  • Customer concentration. One order (₹47.52 Cr) equals about 26% of FY26 revenue (derived), so the loss of one account would be material.
  • Sector margin stress. KSE swung to a ₹3.73 Cr loss in Q4 FY26 and saw a 97% profit decline in Q1 FY27, signalling industry-wide pressure.
  • Rising leverage. Short-term borrowings reached ₹25.50 Cr in June 2026 from nil in March 2025, and finance costs rose to ₹48.21 lakh in Q1 FY27.
  • Continued dilution. Authorised capital is being raised to ₹70 Cr (35 Cr shares) against 18.12 Cr shares outstanding (AGM Notice 2026).
  • Related-party merger risk. The proposed amalgamation of the promoter entity, Healthy Biosciences Ltd, has no disclosed valuation (Feb 2026).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
19 Apr 2025Board meeting (first of 9 in FY26) Corporate Governance Report FY26Routine governance
26 May 2025Board approves FY25 audited results: revenue ₹114.7 Cr (+43%), PAT ₹3.37 Cr (+56%) Directors' Report FY26; TorusSecond consecutive year of strong growth
May–Jun 2025FY25 results published in an English newspaper later than the 48 hours required by Reg. 47 Directors' Report FY26, item 26Compliance lapse flagged by the secretarial auditor
1 Jul 2025Board meeting Corporate Governance Report FY26Routine
14 Aug 2025Q1 FY26 results: sales ₹31.27 Cr (+22% YoY), PAT ₹0.78 Cr (+66%) Business StandardSteady first quarter
14 Aug 2025Gursimran Singh re-designated Whole-Time Director Directors' Report FY26Leadership formalisation
26 Aug 2025₹25 Cr repeat order from a leading dairy cooperative; stock up about 17% intraday to ₹5.94; new plant on track for Nov 2025 DSIJ; HDFC SkyLarge order supporting H2 ramp-up
29 Aug 2025SDK & Associates proposed as secretarial auditor (FY26–FY30); 15th AGM notice Screener (NSE announcement summary)Governance
17 Sep 2025₹4.8 Cr cattle feed order DSIJOrder flow
29 Sep 202515th AGM held (14 special resolutions passed, per the Corporate Governance Report) Corporate Governance Report FY26Shareholder approvals
1 Nov 2025Board meeting Corporate Governance Report FY26Routine
13 Nov 2025Q2 FY26 results: revenue ₹31.74 Cr, PAT ₹0.93 Cr; H1 revenue ₹63.00 Cr, PAT ₹1.71 Cr NSE integrated filingFlat sequential revenue before the new capacity
Late 2025Successful trial run of the new plant announced TipRanksCapacity to 1.8 lakh MTPA
19 Dec 2025Stock at ₹4.23, down about 43% YoY ICICI DirectWeak sentiment despite growth
27 Dec 2025Board meeting Corporate Governance Report FY26Routine
30 Jan 2026Q3 FY26 results: sales ₹58.75 Cr (+73% YoY), PAT ₹1.65 Cr (+126%), OPM 5.16% Capital Market/ArihantPeak quarter of FY26
1 Feb 2026Stakeholders' Relationship Committee meets; zero investor complaints for the year Corporate Governance Report FY26Governance
9 Feb 2026Largest-ever order (₹47.52 Cr) from an existing customer; new Khanna plant in commercial production; 9M FY26 revenue ₹122.87 Cr and PAT ₹3.37 Cr Indian Pharma Post; AliceblueMajor order; stock rose about 12%
9–10 Feb 2026Board discusses merger of Healthy Biosciences Ltd into Ajooni Indian Pharma Post; AliceblueRelated-party corporate action under consideration
1 Mar 2026Independent Directors' meeting Directors' Report FY26Governance
28 May 2026FY26 audited results: revenue ₹182.4 Cr (+59%), PAT ₹4.32 Cr (+28%); Q4 PAT ₹94.72 lakh; cash down to ₹41.90 lakh from ₹683.02 lakh; borrowings ₹17.76 Cr NSE filing; ScanXGrowth with weaker cash and higher leverage
May–Jun 2026Promoters confirm no encumbrance during FY26 ScanXPositive governance signal
8 Jun 2026Stock hits 52-week low of ₹3.40 VenturaSentiment trough
22 Jun 2026Trading window closure filed Financial filings listingRoutine
29 Jun 2026Board approves increase in authorised capital to ₹70 Cr and ₹3.87 Cr preferential issue to Healthy Biosciences; Articles amended AGM Notice 2026Promoter funding plus headroom for further issuance
1 Jul 2026Annual Report FY2025-26 filed with NSE NSE archiveDisclosure
14 Jul 2026Reg. 74(5) certificate for Q1 FY27 filed (a late FY26 filing had been flagged by the secretarial auditor) Sharpely (NSE feed)Compliance
29 Jul 202616th AGM held by video conference; all special resolutions passed (results declared 31 Jul) NSE filing 31 Jul 2026Approvals
12 Aug 202690,00,000 shares allotted to Healthy Biosciences at ₹4.30 NSE filingPromoter holding up from 26.89% to 30.53%
14 Aug 2026Q1 FY27 results: revenue ₹63.49 Cr (+103% YoY), PAT ₹43.18 lakh (−45% YoY); short-term borrowings ₹25.50 Cr NSE filingMargin compression and leverage rising
Aug–Sep 2026Stock trades at ₹3.62–3.96; market cap about ₹65–70 Cr Sharpely; Anand Rathi; TorusValuation near 0.7x book

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Income Statement: Revenue & Gross Profit: Revenue from operations rose from INR 740.4 Mn in FY2022 to INR 1,823.8 Mn in FY2026.
AJOONI BIOTECH LTD — Income Statement: Revenue & Gross Profit
Series (INR Mn)FY2022FY2023FY2024FY2025FY2026
Revenue from operations740.4744.9801.11,146.91,823.8
Gross profit — revenue minus materials100.387.597.6176.7344.6

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.